
Remibrutinib reduced relapse rates and improved disease progression rates

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The new centre will be home to nearly 2,000 world-class researchers and scientists

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

The results from a global phase 3 trial show the longest survival data ever reported in this setting

MS affects nearly three million people worldwide and has three main types